Clinical Trial: Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers

This study is no longer recruiting patients.

Sponsors and Collaborators: National Cancer Institute (NCI)
Johns Hopkins Oncology Center
Information provided by: National Cancer Institute (NCI)


RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bone marrow transplantation may be able to replace immune cells that have been destroyed by radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Mycophenolate mofetil and tacrolimus may be an effective treatment for graft-versus-host disease caused by bone marrow transplantation. PURPOSE: Phase II trial to study the effectiveness of total-body irradiation, tacrolimus, and mycophenolate mofetil plus bone marrow transplantation in treating patients with hematologic cancers.

Condition Treatment or Intervention Phase
Multiple Myeloma
 Drug: mycophenolate mofetil
 Drug: tacrolimus
Phase II

MedlinePlus related topics:  Leukemia, Adult Acute;   Leukemia, Adult Chronic;   Leukemia, Childhood;   Lymphoma;   Multiple Myeloma

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Total Body Irradiation, Tacrolimus, and Mycophenolate Mofetil With HLA Identical Related Donor Bone Marrow Transplantation

Further Study Details: 

Study start: August 1998

OBJECTIVES: I. Determine whether sustained engraftment of HLA identical sibling marrow can be achieved in patients treated with total body irradiation before transplant and tacrolimus and mycophenolate mofetil after transplant. II. Document the nonhematologic toxicities of this regimen. III. Characterize immune reconstitution of patients during this treatment regimen. IV. Document the incidence of aplasia and graft-versus-host disease associated with donor leukocyte infusions when administered after this regimen.

PROTOCOL OUTLINE: Patients receive total body irradiation in a single fraction on day -1. Tacrolimus is given orally twice per day on days -1 to 50. Mycophenolate mofetil is given orally on day 0 and twice per day on days 1 to 28. Patients receive donor bone marrow infusion on day 0. Patients are evaluated on days 56, 180, 292, and 365. If there is donor engraftment, donor chimerism is less than 80%, there is no active graft-versus-host disease, no disease progression, less than 50% decrease in donor cell chimerism from last measurement, and the patient is not taking immunosuppressive agents, then donor leukocyte infusions are administered on days 70, 194, and 306. Patients are followed annually for 5 years.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.


Ages Eligible for Study:  18 Years   -   70 Years



--Disease Characteristics--

--Prior/Concurrent Therapy--

  • See Disease Characteristics

--Patient Characteristics--

  • Age: 18 to 70
  • Performance status: ECOG 0-2
  • Life expectancy: Not specified
  • Hematopoietic: Not specified
  • Hepatic: Bilirubin less than 3.1 mg/dL
  • Renal: Creatinine less than 3.1 mg/dL
  • Cardiovascular: LVEF at least 35%
  • Pulmonary: FEV1 and FVC at least 40% of predicted (60% for patients who have received thoracic or mantle radiotherapy)
  • Other: Not pregnant; Fertile patients must use effective contraception; Not HIV positive

Location Information

      Johns Hopkins Oncology Center, Baltimore,  Maryland,  21231-2410,  United States

Study chairs or principal investigators

Ephraim J. Fuchs,  Study Chair,  Johns Hopkins Oncology Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000066639; JHOC-98070603; NCI-H98-0023; JHOC-9845
Record last reviewed:  February 2004
Last Updated:  October 13, 2004
Record first received:  November 1, 1999 Identifier:  NCT00003572
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005